Oruka Therapeutics (NASDAQ:ORKA) Given Buy Rating at HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $120.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 40.55% from the stock’s current price.

Several other equities analysts have also commented on the company. UBS Group increased their price objective on Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Guggenheim set a $200.00 price target on shares of Oruka Therapeutics and gave the stock a “buy” rating in a research note on Monday, April 27th. Piper Sandler restated an “overweight” rating and issued a $180.00 target price on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Thursday, May 14th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $131.30.

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $85.38 on Tuesday. Oruka Therapeutics has a 52-week low of $10.77 and a 52-week high of $91.00. The company has a fifty day moving average of $65.16 and a 200-day moving average of $45.89. The company has a market capitalization of $5.15 billion, a P/E ratio of -44.01 and a beta of -0.25.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. As a group, analysts forecast that Oruka Therapeutics will post -2.06 EPS for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.69, for a total value of $120,494.01. Following the completion of the transaction, the chief executive officer owned 925,580 shares in the company, valued at approximately $64,503,670.20. This represents a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joana Goncalves sold 7,947 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.28, for a total transaction of $550,568.16. Following the completion of the transaction, the insider owned 32,718 shares of the company’s stock, valued at approximately $2,266,703.04. The trade was a 19.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 185,407 shares of company stock worth $11,636,307. 23.49% of the stock is currently owned by company insiders.

Institutional Trading of Oruka Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ORKA. Legal & General Group Plc purchased a new position in Oruka Therapeutics during the second quarter valued at $28,000. BNP Paribas Financial Markets grew its stake in shares of Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after acquiring an additional 2,306 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Oruka Therapeutics during the fourth quarter valued at $37,000. Finally, PNC Financial Services Group Inc. bought a new position in shares of Oruka Therapeutics during the third quarter valued at $39,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.